Drug Profile


Alternative Names: anti-FLT3 Mab-gelonin; EB10-Gelonin; IMC-EB10; IMC-EB10-gelonin

Latest Information Update: 09 Feb 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ImClone Systems
  • Developer ImClone Systems; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Fms-like tyrosine kinase 3 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Acute myeloid leukaemia

Most Recent Events

  • 24 Jan 2011 Discontinued - Phase-I for Acute myeloid leukaemia in USA (IV)
  • 20 Dec 2010 ImClone completes enrolment in its phase I trial [NCT00887926] for Acute myeloid leukaemia in US
  • 05 Jun 2009 Phase-I clinical trials in Acute myeloid leukaemia in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top